[{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"||GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"SGLT2","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Integrated Nanotherapeutics","sponsor":"Breakthrough T1D","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Integrated Nanotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Integrated Nanotherapeutics \/ Breakthrough T1D","highestDevelopmentStatusID":"4","companyTruncated":"Integrated Nanotherapeutics \/ Breakthrough T1D"},{"orgOrder":0,"company":"Sernova","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sernova \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Sernova \/ AstraZeneca"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PreveCeutical Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : DehydraTECH-liraglutide is an orally administered drug candidate , which is currently being investigated for the treatment of diabetes mellitus and obesity.

                          Product Name : DehydraTECH-liraglutide

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : BNT24005 (semaglutide) is a sublingual film which delivers glucagon-like peptide-1 (GLP-1) receptor agonist indicated for type 2 diabetes.

                          Product Name : BNT24005

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Oral DehydraTECH-technology processed liraglutide (GLP-1 agonist) is being investigated for obesity in comparison with Rybelsus (semaglutide).

                          Product Name : DehydraTECH-liraglutide

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          November 20, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Oral DehydraTECH-technology processed semaglutide and liraglutide (GLP-1 agonist) is being investigated for obesity.

                          Product Name : DehydraTECH-liraglutide

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 24, 2024

                          Lead Product(s) : Liraglutide,Semaglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.

                          Product Name : DehydraTECH-liraglutide

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 22, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The company will advance INT's technology which employs multi-cargo LNP to deliver multiple antigens using mRNA, along with immune-modifying small molecules, to re-train the immune system in T1D.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 09, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Breakthrough T1D

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.

                          Product Name : DehydraTECH-Liraglutide

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          August 22, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the collaboration, AstraZeneca will explore the use of Sernova’s Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.

                          Product Name : TFC-039

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : TFC-039

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Wanbang Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The patent application, entitled “Use of Ketamine in the Treatment of Diabetes and Obesity,” identifies protein bindings and interactions with ketamine leading to the discovery of ketamine as a potential treatment for Type 2 diabetes and obesity.

                          Product Name : Ketarx

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 27, 2021

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank